Zacks Investment Research
14 Oct 2026, 18:41 UTC · 1h ago
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Impact · against what's priced in
The settlement is a net negative for LQDA as it imposes a $380.7 million cash drain and restricts the Yutrepia label, undermining near-term profitability and growth. UTHR benefits from a significant cash windfall and the successful defense of its patents.
- LQDA−0.50
Challenges what's priced in
- The price assumes
Near-term profitability, as the price reflects the recent achievement of positive net income
The requirement to pay $380.7 million in installments through 2027 directly threatens the net income and operating margins the market currently assumes.
What LQDA's price assumes · Sep 13
Search tags
